Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib
Qinhua Huang(Pfizer (United States)), Martin P. Edwards(Pfizer (United States)), Benjamin J. Burke(Pfizer (United States)), Paul Richardson(Pfizer (United States)), Alexei Brooun(Pfizer (United States)), Laura Lingardo(Pfizer (United States)), Huichun Zhu(Pfizer (United States)), Kevin N. Dack(Pfizer (United States)), Justine L. Lam(Pfizer (United States)), Helen Y. Zou(Centre for Cancer Biology), Melissa West Lu(Pfizer (United States)), Michele McTigue(Pfizer (United States)), Robert S. Kania(Pfizer (United States)), Michael R. Collins(Pfizer (United States)), Ted W. Johnson(WorldFish), Kevin D. Bunker(Pfizer (United States)), Hong Shen(University of Michigan), Judith G. Deal(Pfizer (United States)), Sergei Timofeevski(Pfizer (United States)), Neal W. Sach(Pfizer (United States)), Simon Bailey(Newcastle University), J. Jean Cui(Unknown), Patrick S. Johnson(Pfizer (United States)), Lars D. Engstrom(Mirati Therapeutics (United States)), Wei Liu(Beijing Institute of Fashion Technology), Hui Wang(Pfizer (United States)), Ya‐Li Deng(Pfizer (United States)), Mingying He(Pfizer (United States)), Robert L. Hoffman(Pfizer (United States)), Qiuhua Li(Pfizer (United States)), Graham L. Smith(Pfizer (United States)), Cynthia L. Palmer(Pfizer (United States)), JinJiang Zhu(Pfizer (United States)), Phuong Le, Dac M. Dinh(Pfizer (United States)), Jacqui Hoffman(Pfizer (United States)), Albert Stewart(Pfizer (United States)), Hieu Lam(Pfizer (United States)), Konstantinos Tsaparikos(Pfizer (United States)), Andrew S. Cook(Pfizer (United States)), Tod Smeal(Pfizer (United States))
Cited by 118
Related Papers
Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma
|Nature|2019|982
An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms
|Cancer Research|2007|750
Risk stratification of childhood medulloblastoma in the molecular era: the current consensus
|Acta Neuropathologica|2016|650